✦ LIBER ✦

P525 Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience

✍ Scribed by Santos-Antunes, J.; Magro, F.; Vilas-Boas, F.; Rodrigues-Pinto, E.; Coelho, R.; Ribeiro, O.; Lopes, S.; Macedo, G.

Book ID: 122064374
Publisher: Oxford University Press
Year: 2014
Tongue: English
Weight: 52 KB
Volume: 8
Category: Article
ISSN: 1873-9946
DOI: 10.1016/S1873-9946(14)60645-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Crohn's disease outcome in patients unde

Crohn's disease outcome in patients under azathioprine: A tertiary referral center experience

✍ Magro, Fernando; Santos-Antunes, João; Vilas-Boas, Filipe; Rodrigues-Pinto, Edua 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 695 KB

P395 Perianal Crohn's disease – Experien

P395 Perianal Crohn's disease – Experience of a tertiary referral center

✍ Fernandes, S.; Sousa, P.; Moura, M.; Correia, L.; Rita Gonçalves, A.; Moura Sant 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 50 KB

P405 Predictors of endoscopic recurrence

P405 Predictors of endoscopic recurrence in a long term follow up cohort of Crohn's disease patients – How effective is azathioprine? A single tertiary referral center experience

✍ Erzin, Y.; Sisman, G.; Hatemi, I.; Baca, B.; Hamzaoglu, I.; Dirican, A.; Celik, 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 92 KB

P398 Outcome of treatment with biologica

P398 Outcome of treatment with biological agents in Crohn's disease: 117 patients in 5 years from a tertiary referral center

✍ Ramos, L.; Hernandez Camba, A.; Carrillo Palau, M.; Alonso, I.; Hernandez Alvare 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 51 KB

Vulval Crohn's disease: A tertiary cente

Vulval Crohn's disease: A tertiary center experience of 23 patients

✍ J. Landy; S.T.C. Peake; A. Akbar; A.L. Hart 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB 👁 1 views

s disease (CD) affecting the vulva is often unrecognized and can be difficult to treat. The majority of cases reported describe metastatic CD, where the vulval inflammation is not contiguous with the gastrointestinal tract. Overall, only 56 cases of vulval CD are reported in the literature since the

Predictors of adalimumab dose escalation

Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center

✍ Russell D. Cohen; Jeffrey R. Lewis; Hannah Turner; Laura E. Harrell; Stephen B. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views

Background: Pivotal trials for adalimumab (ADA) demonstrated effectiveness versus placebo for induction and maintenance of remission in moderate to severely active Crohn's disease (CD). Although the approved maintenance regimen in the U.S. is 40 mg subcutaneously every 14 days, some patients require